Getting a sterile injectable product from early development to commercial supply has never been simple. But today, sponsors are dealing with more pressure on almost every front: tighter timelines, more complex molecules, changing supply routes, higher demand for injectable capacity, and greater scrutiny around where and how products are made.
This eBook looks at how those pressures are changing development strategy. It covers practical issues that can shape a sterile program from the start, including formulation choices, stability planning, fill-finish readiness, delivery formats, cold chain needs, and supply chain resilience.
In this eBook, you’ll learn:
How to build resilience into sterile drug development from the earliest stages
Why integrated planning across formulation, manufacturing, packaging, and supply is critical
How strategic sourcing and supplier partnerships can reduce global supply chain risk
What formulation and delivery strategies can accelerate injectable products from the clinic to commercialization
Thermo Fisher’s Alessandro Chreim discusses why sponsors need to connect formulation, fill-finish, packaging, clinical supply, and commercial planning earlier in the development process.
In an increasingly complex global landscape, pharmaceutical companies face heightened risks in their supply chains due to natural disasters, geopolitical tensions, and regulatory changes.
